EVAXION BIOTECH
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.
EVAXION BIOTECH
Social Links:
Industry:
Biotechnology
Founded:
2008-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.evaxion-biotech.com
Total Employee:
11+
Status:
Active
Total Funding:
57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Google Maps Pound Sterling New Relic
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
ProtActivity
ProtActivity focusses on the development of vaccines against protozoal diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Stock Details
Investors List
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Evaxion Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer |
Official Site Inspections
http://www.evaxion-biotech.com Semrush global rank: 6.69 M Semrush visits lastest month: 867
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Evaxion Biotech"
About Evaxion - Leading AI-Driven Vaccine Development - Evaxion …
He is a well-respected name in pharma and biotech Business Development community with over 40 years of experience. He held business development and managerial positions at Evaxion …See details»
Evaxion Biotech - Crunchbase Company Profile
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. ... 9,893 Number of …See details»
Evaxion Biotech A/S - LinkedIn
Evaxion Biotech A/S | 9,402 followers on LinkedIn. ... Life Science Connect, a student-driven non-profit organization in the Nordics which has previously hosted similar events with over 500 ...See details»
OUR PARTNERSHIPS - Evaxion Biotech
In September 2023, Evaxion entered a discovery partnership with Afrigen Biologics and the recently created mRNA Vaccine Technology Transfer Hub. The hub was established by the …See details»
Evaxion to present preclinical Proof-of-Concept for precision ERV ...
5 hours ago COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI …See details»
Evaxion to present preclinical Proof-of-Concept for - GlobeNewswire
Feb 12, 2024 Contact information Evaxion Biotech A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected] . About EVAXIONSee details»
Revolutionizing Vaccine Discovery: New Data Validates ... - Evaxion …
Sep 11, 2023 Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development Evaxion's AI model predicts vaccine efficacy in infectious disease …See details»
Using AI to create a vaccine revolution - Nature
Clinical stage company Evaxion Biotech is using artificial intelligence (AI) to simulate the immune system and create predictive models to identify novel targets for vaccines against bacterial and ...See details»
Evaxion Partners With Pharmaceutical Company Afrigen Biologics …
Sep 20, 2023 The World Health Organization (WHO) ... About EVAXION Evaxion Biotech A/S is a clinical-stage biotech company developing world-leading AI platforms. Evaxion's proprietary …See details»
Evaxion to Unveil Potentially Groundbreaking AI-Immunology
Nov 28, 2023 About EVAXION Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction …See details»
Evaxion - Nature
The clinical stage biotech Evaxion’s aim is to lead ... According to the World Health Organization (WHO), cases of super-gonorrhea are emerging, withresistancetoceftriaxone,azithromycin,peni-See details»
Evaxion to present preclinical Proof-of-Concept for precision ERV ...
5 hours ago Contact information Evaxion Biotech A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected] . About EVAXION …See details»
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a …
Jan 24, 2024 Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power …See details»
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its ...
Oct 31, 2023 Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power …See details»
Evaxion to present preclinical Proof-of-Concept for precision ERV ...
18 hours ago Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models …See details»
Evaxion to present preclinical Proof-of-Concept for precision ERV ...
5 hours ago [email protected] About EVAXION. Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI …See details»
Evaxion Biotech A/S (EVAX) Earnings Date and Reports 2025
Nov 8, 2024 Evaxion Biotech A/S issued Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.04, which beat the consensus estimate of -$0.12 by $0.08. Quarterly revenue was …See details»
Evaxion Biotech | Globenewswire
Feb 12, 2024 Evaxion Biotech A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected] . About EVAXION Evaxion …See details»
Evaxion Biotech: Evaxion to present preclinical Proof-of-Concept …
5 hours ago Contact information Evaxion Biotech A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected].See details»